VERA Stock Overview
A clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Vera Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$47.03 |
| 52 Week High | US$51.61 |
| 52 Week Low | US$12.28 |
| Beta | 1.02 |
| 11 Month Change | 15.52% |
| 3 Month Change | 19.67% |
| 1 Year Change | 257.37% |
| 33 Year Change | 77.47% |
| 5 Year Change | n/a |
| Change since IPO | 308.96% |
Recent News & Updates
Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?
Oct 07
Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients
Oct 04Recent updates
Is Vera Therapeutics (NASDAQ:VERA) A Risky Investment?
Oct 07Vera: Potential First Of Atacicept As A B-Cell Modulator For IgAN Patients
Oct 04Vera Therapeutics' Atacicept: A Potential Game-Changer In IgA Nephropathy
Jul 22Is Vera Therapeutics (NASDAQ:VERA) Using Debt In A Risky Way?
Jul 05Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect
Jan 25Vera Therapeutics: Under The Radar IgAN Player Has Much To Prove
Sep 06Vera Therapeutics GAAP EPS of -$0.55 beats by $0.17
Aug 10Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth
Feb 16Vera: Biotech With 3 Mid-Stage Programs With Potential For Success
Jan 19Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot
Jan 07We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth
Oct 25Vera Therapeutics soars 16% on three new favorable view from analysts
Jun 08Shareholder Returns
| VERA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.0% | -3.7% | 0.3% |
| 1Y | 257.4% | 15.2% | 31.1% |
Return vs Industry: VERA exceeded the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: VERA exceeded the US Market which returned 30.3% over the past year.
Price Volatility
| VERA volatility | |
|---|---|
| VERA Average Weekly Movement | 8.5% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VERA has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: VERA's weekly volatility (8%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 82 | Marshall Fordyce | veratx.com |
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections.
Vera Therapeutics, Inc. Fundamentals Summary
| VERA fundamental statistics | |
|---|---|
| Market cap | US$2.90b |
| Earnings (TTM) | -US$134.38m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-22.2x
P/E RatioIs VERA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VERA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$134.38m |
| Earnings | -US$134.38m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.12 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 17.5% |
How did VERA perform over the long term?
See historical performance and comparison